Compare Divis Laboratories with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GSK PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GSK PHARMA DIVIS LABORATORIES/
GSK PHARMA
 
P/E (TTM) x 31.6 52.9 59.7% View Chart
P/BV x 7.1 11.1 64.0% View Chart
Dividend Yield % 0.6 1.4 44.3%  

Financials

 DIVIS LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
GSK PHARMA
Mar-19
DIVIS LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1423,595 31.8%   
Low Rs5331,253 42.5%   
Sales per share (Unadj.) Rs146.6184.7 79.4%  
Earnings per share (Unadj.) Rs33.026.3 125.6%  
Cash flow per share (Unadj.) Rs38.429.2 131.7%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.20.8 144.7%  
Book value per share (Unadj.) Rs222.8126.3 176.4%  
Shares outstanding (eoy) m265.47169.40 156.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.713.1 43.5%   
Avg P/E ratio x25.392.2 27.5%  
P/CF ratio (eoy) x21.883.1 26.2%  
Price / Book Value ratio x3.819.2 19.6%  
Dividend payout %30.376.1 39.8%   
Avg Mkt Cap Rs m222,318410,626 54.1%   
No. of employees `00010.85.0 217.0%   
Total wages/salary Rs m4,5615,372 84.9%   
Avg. sales/employee Rs Th3,616.06,306.7 57.3%   
Avg. wages/employee Rs Th423.81,083.1 39.1%   
Avg. net profit/employee Rs Th814.9898.0 90.7%   
INCOME DATA
Net Sales Rs m38,91531,281 124.4%  
Other income Rs m1,1341,023 110.9%   
Total revenues Rs m40,04932,304 124.0%   
Gross profit Rs m12,6176,009 210.0%  
Depreciation Rs m1,425486 293.2%   
Interest Rs m136 221.7%   
Profit before tax Rs m12,3136,540 188.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m3,5432,373 149.3%   
Profit after tax Rs m8,7704,454 196.9%  
Gross profit margin %32.419.2 168.8%  
Effective tax rate %28.836.3 79.3%   
Net profit margin %22.514.2 158.3%  
BALANCE SHEET DATA
Current assets Rs m45,35120,061 226.1%   
Current liabilities Rs m6,50714,543 44.7%   
Net working cap to sales %99.817.6 565.8%  
Current ratio x7.01.4 505.2%  
Inventory Days Days12757 223.2%  
Debtors Days Days9514 676.7%  
Net fixed assets Rs m21,16014,343 147.5%   
Share capital Rs m5311,694 31.3%   
"Free" reserves Rs m58,62519,704 297.5%   
Net worth Rs m59,15621,398 276.5%   
Long term debt Rs m02 0.0%   
Total assets Rs m67,83239,113 173.4%  
Interest coverage x926.81,091.0 85.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 71.7%   
Return on assets %12.911.4 113.6%  
Return on equity %14.820.8 71.2%  
Return on capital %20.831.9 65.3%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,359534 6,059.7%   
Fx outflow Rs m9,0427,091 127.5%   
Net fx Rs m23,317-6,557 -355.6%   
CASH FLOW
From Operations Rs m7,7593,994 194.3%  
From Investments Rs m-4,783-1,433 333.7%  
From Financial Activity Rs m-3,142-3,584 87.7%  
Net Cashflow Rs m-166-1,023 16.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 11.8 10.2 115.7%  
FIIs % 19.0 23.8 79.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 15.4 111.7%  
Shareholders   31,796 102,036 31.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Yes Bank & Tata Steel Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Despite the cool-off in global oil prices, benchmark indices struggled as foreign investors.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 19, 2019 12:23 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS